InvestorsHub Logo
Followers 48
Posts 9781
Boards Moderated 1
Alias Born 01/31/2008

Re: CATTDOGG12347 post# 92176

Thursday, 02/07/2019 4:48:26 PM

Thursday, February 07, 2019 4:48:26 PM

Post# of 108192
Fact checking the ALL CAPS

What Dr. Petit actually said: “These preliminary data suggest our approach may be among the best-in-class for CD8+ T cell response which we believe is important for successful clinical outcomes.”

RAPID AND BROAD ANTI-TUMOR RESPONSE!

What is rapid and broad is the production of CD8+ T cells...whether that translates into an anti-tumor response has yet to be proven and is a matter of faith. As Petit said, "we believe..."

FIRST IN CLASS ANTI-TUMOR RESPONSE

There is no independent ranking, and ADXS did NOT say it was first, it said it was AMONG the first class...which begs the question, who are the comparison products. If this is cutting edge tech, there may be only two other products out there, and ADXS could be third and still be "among the best".

You have to ask yourself, "Do I feel lucky?" Well, do you short punk?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News